Navigation Links
Bradmer announces 2008 fourth quarter and fiscal year operational and financial results
Date:3/31/2009

res have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

    Financial results are included below:


    Bradmer Pharmaceuticals Inc.
    Balance Sheets
    US $
                                                   December 31,  December 31,
                                                          2008          2007
                                                   ------------  ------------
    Assets

    Current
      Cash and cash equivalents                    $ 8,245,455   $19,469,337
      Amounts receivable                                12,520       143,722
      Prepaid expenses and other assets                 27,158        24,029
                                                   ------------  ------------

                                                     8,285,133    19,637,088

    Patent rights                                      711,054       685,165
                                                   ------------  --
'/>"/>
SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Bradmer implements cash conservation plan
2. Bradmer provides clinical trial update and announces evaluation of strategic alternatives
3. Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference
4. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
5. Bradmer announces 2008 third quarter operational and financial results
6. Bradmer to present at Rodman & Renshaw Healthcare Conference
7. Bradmer receives FDA approval to proceed with Phase III clinical trial
8. Bradmer announces 2008 first quarter operational and financial results
9. Bradmer announces new additions to management team
10. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
11. Notice of Bradmer Pharmaceuticals Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... As residents and business owners ... Burns and Carita Weaver, believe in supporting local ... the Southlake Chamber of Commerce, Carroll Independent School ... launched a website for Southlake mayoral candidate Laura ... tool for Hill’s campaign, the website combines images, ...
(Date:3/1/2015)... 2015 Adults who are not legally ... term or universal policies can now use the QuotesPros.com ... life insurance companies for single adults can now be ... http://quotespros.com/life-insurance.html . , The rate plans that nationwide agencies ... to a number of life protection policies. The term, ...
(Date:3/1/2015)... York, NY (PRWEB) March 01, 2015 ... has grown substantially over the past few weeks in ... LLP are actively filing claims, the Firm announces. ... reflects 7,713 cases in the Bergen County proceeding established ... Inc., compared with a few weeks earlier, when 90 ...
(Date:3/1/2015)... Theme and plugin developers from Pixel ... pack for Final Cut Pro X entitled Transccordion. , ... any FCPX editors project.” Said Christiana Austin, CEO of ... needed to easily drag and drop their accordion transition ... different controls over the parameters of this transition bundle ...
(Date:2/28/2015)... Dallas, TX (PRWEB) March 01, 2015 ... is estimated that 10 percent of urban adult population ... some form of heart diseases and 20-30 percent of ... due to heart ailments and coronary vascular diseases (CVD). ... has launched a new market research report titled “Indian ...
Breaking Medicine News(10 mins):Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2Health News:Best Life Insurance Companies for Single Adults Now Searchable at Insurance Website 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3
... (OTCBB:PVCT) announced that it has obtained approval to begin Phase ... III and IV metastatic melanoma, the most aggressive and deadly ... evaluate efficacy of Provecta in a total of 80 subjects. ... into up to 20 tumors in each subject. Additional treatment ...
... 6 Nuvelo, Inc.,(Nasdaq: NUVO ) today ... in September: Bank of America 37th Annual ... PT Dr. Ted W. Love, Chairman and ... Breakout: http://www.veracast.com/webcasts/bas/37th-annual-2007/id89117822.cfm ...
... Purchase Vehicles, HARRISBURG, Pa., Sept. 5 ... people with disabilities will be,better able to get ... in 27,human service transportation providers. The organizations will ... citizens and people with disabilities deserve the same ...
... of two of Pittsburgh,s,finest long term care providers ... within one health care system. Today, the,Sisters of ... Charity announced,that they will integrate Marian Manor Corporation, ... operated by the Sisters of the Holy Spirit, ...
... N.J., Sept. 6 MedQuist Inc.,(Pink Sheets: ... technology and services, announces the re-launch of ... site has been completely redesigned with,assistance from ... Scott Bennett, MedQuist senior vice president of ...
... in 10 Students Suffer Chronic Back Pain Related ... With two weeks to go until the,annual National ... United States are gearing up to help students,"Pack ... by the American,Occupational Therapy Association (AOTA), is set ...
Cached Medicine News:Health News:Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation 2Health News:Governor Rendell Announces $2.1 Million Investment in Small Transit Vehicles 2Health News:Governor Rendell Announces $2.1 Million Investment in Small Transit Vehicles 3Health News:Area Health Care Providers Announce Plans to Integrate Services 2Health News:MedQuist Re-launches New, Improved Web Site 2Health News:Two Weeks Until National School Backpack Awareness Day 2
(Date:2/27/2015)... Feb. 27, 2015  Boston Scientific Corporation (NYSE: ... Barclays 2015 Annual Healthcare Conference on March 10 in ... Dan Brennan , executive vice president and chief financial ... Relations, will participate in a 25-minute question and answer ... approximately 1:05 p.m. ET. Following a 5-minute break, a ...
(Date:2/27/2015)...  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the fourth quarter and full year ended December ... year for PTC. We are now a growing commercial-stage ... in the rare disease space," stated Stuart W. Peltz, ... proud to bring the first treatment for Duchenne muscular ...
(Date:2/27/2015)... NEWTON, Mass. and JERUSALEM ... privately-held biopharma company developing octreotide capsules, its lead product ... of a $70 million Series E financing round. Participants ... and Sofinnova Ventures, and an undisclosed blue chip public ... F2 Capital, 7 Med Health Ventures, Abingworth and ARCH ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... Vical Incorporated (Nasdaq:,VICL) today reported financial results for the ... of 2007 were $3.1 million, compared with,revenues of $7.3 ... loss for,the second quarter of 2007 was $8.2 million, ... $3.2 million, or $0.11 per share, for the second ...
... Vaccine to be tested with ... ImmuneRegen,s ... owned subsidiary of IR BioSciences Holdings, Inc.,(OTC Bulletin Board: IRBO), ... VaxGen Inc. (Pink Sheets: VXGN.PK). As part,of the agreement, ImmuneRegen ...
Cached Medicine Technology:Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 2Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 3Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 4Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 5Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 6ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc. 2ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc. 3ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc. 4
... Bausch & Lomb PreserVision® AREDS formula ... and mineral supplement clinically proven effective in ... Age Related Eye Disease Study (AREDS). , ... and mineral supplement with the antioxidant vitamins ...
Ocuvite® vitamin and mineral supplements contain 2 mg of Lutein 8 times more than the leading multivitamins. Ocuvite also contains vitamin antioxidants A, C and E, as well as the minerals zinc, ...
HydroEye is an exclusive formulation designed to provide dry eye relief and support the body's natural tear formation. Like all ScienceBased Health formulations, it is produced in softgel form for ma...
Easy-to-use desktop QC data management solution...
Medicine Products: